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ABSTRACT
Objective: The purpose of this study was to assess the incidence and pattern of adverse drug reactions (ADRs) reported from the department of 
neurology of a tertiary care hospital in Karnataka, India.
Methods: It is a hospital-based prospective, observational study, conducted among the inpatients of all age groups of either sex for a period of 
6 months. ADRs were reported by the clinical pharmacists and physicians of this hospital. ADRs obtained were categorized based on its causality, 
severity, preventability, predictability, and outcomes. Binary logistic regression was carried out to identify the predictors of ADR and Kaplan–Meier 
analysis was performed for survival analysis.
Results: A total of 250 patients were enrolled for the study in which 108 (43%) patients were presented with at least one ADR and a total of 212 
ADRs were observed. The highest rate of ADRs was observed with antiepileptics 61 (29.5%). The most commonly reported ADRs were skin reactions 
23 (10.8%). Causality was assessed using three different scales which showed that most of the ADRs were probable. Severity, preventability, and 
predictability were assessed, of which 125 (59%) ADRs were moderate, 192 (90.6%) ADRs were probably preventable, and 156 (73.6%) ADRs 
were predictable, respectively. The outcomes showed that 150 (70.1%) patients recovered from the reactions. Predictors such as polypharmacy and 
duration of stay were found to be significant.
Conclusion: The study concluded that the prevalence of ADRs in the department of neurology is high. Thus, early detection and management of ADRs 
are essential to avoid further complications of the reaction.
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INTRODUCTION
Clinical evolution of medications is a convoluted procedure which 
consumes both resources and time. During the diverse periods of clinical 
trials, the medications are tried for its transient safety and efficacy 
on a set number of deliberately chosen people. After the medication 
is affirmed for utilization by overall population, post-marketing 
surveillance helps to recognize the new adverse drug reactions (ADRs) 
related to the utilization of various medicated formulations [1]. An ADR 
is defined as “any response to a drug that is noxious and unintended, 
and that occurs at doses normally used in man for the prophylaxis, 
diagnosis, or therapy of disease, or for the modifications of physiological 
function” [2]. Monitoring of ADRs helps to evaluate the effectiveness 
and risk of medications, empower safe and rational use of drugs and 
enhance general patient care and well-being. The cost of ADRs in the 
community is high, and under-reporting of ADRs by health experts is a 
globally perceived issue. ADR identification and reporting may prevent 
the occurrence of ADRs and drug-related problems (DRPs) in future [1].
The patient may experience ADRs with single or multiple drugs as 
anticipated or may show up instantly, on continued use, even after 
cessation of therapy. Although ADRs influence all age groups, yet the 
most usually influenced ones are geriatrics and pediatrics. Geriatrics 
experience ADRs due to comorbid diseases, polypharmacy, altered 
pharmacokinetic, and pharmacodynamic changes which enhance 
hospital admissions. Pediatrics particularly neonates experience 
ADRs due to immature organ development and instabilities in 
pharmacokinetics and pharmacodynamics [2,3]. Administration of 
drugs acting on the central nervous system (CNS) during pregnancy may 
manifest potential teratogenic impacts on the fetus. Consumption of 
phenytoin increases the proportion of malformations such as orofacial 
clefts, cardiovascular deformities, and seizures. Medications such as 
carbamazepine, levetiracetam, and lorazepam can reach the fetus through 
breast milk and can harm them [4]. Hepatic and renal impairment with 
comorbidities, genetic polymorphisms, and medications with a narrow 
therapeutic index may demonstrate high occurrences of ADR.
Drugs acting on the CNS such as antiepileptic, antipsychotic, and 
anxiolytic contribute to ADRs such as extrapyramidal symptoms, 
insomnia, sedation, and even serious effects such as increasing suicidal 
tendency and depression [5]. Studies have showed that the patients 
in neurology department experience 23.5% of ADRs [6]. The ADRs 
transpire due to particular idiosyncratic mechanisms or harmful 
metabolic items which may lead to initial treatment failure [7]. ADRs 
can influence the consistence and course of treatment in patients 
exposed to drug therapy. The effect of ADRs can be determined based 
on cessation of therapy, treatment failure or due to an adverse event [8].
An active pharmacovigilance program is the need of the hour in all 
hospitals especially in Indian setup, as ADRs cause a significant burden 
to the patients and also to the economy. This project is aimed to work in 
this regard to monitor, detect, assess, and disseminate the ADRs which 
ensures patient safety and minimizes the cost of health care. Detection 
and monitoring of ADR in the inpatient department of neurology is 
lacking in Indian literature. The objectives of the study were to compare 
the incidence and pattern of ADRs, to detect and assess the causality, 
preventability, predictability, and severity of ADRs, to evaluate the 
management of ADR and to document and report the detected ADR. 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i10.27737
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Thus, the current study improves the knowledge and pattern of ADRs in 
patients with neurological diseases.
METHODS
A hospital-based prospective, observational study was conducted 
among the inpatients of Department of Neurology of Ramaiah Memorial 
Hospital, Bengaluru, Karnataka for over a period of 6 months, from 
November 2016 to April 2017. Patients diagnosed with neurologic 
disorders and treated with one or more neurological agents were 
included in the study and screened for ADRs, irrespective of the 
neurologic diagnosis while samples with inadequate data and patients 
not willing to participate in the study were excluded. The ADRs that 
were identified and reported by clinical pharmacists and physicians 
were recorded. The data obtained include patient demographic 
details, relevant history, general and systemic examination, laboratory 
investigations, diagnosis, treatment, description and nature of reaction, 
date and time of onset of reaction, suspected drugs, severity, treatment 
offered, and outcomes. Permission from Institutional Ethical Committee 
of Ramaiah Medical College was obtained before instigation of the study.
The degree of association of drug and the adverse reaction is determined 
using three different scales, namely Naranjo’s algorithm, World Health 
Organization (WHO) causality assessment scale, and Karch and 
Lasagna’s causality assessment scale. Naranjo’s algorithm involves a 
set of questionnaires, to each of which score has been provided ranging 
from −1 to +2. The total score for a particular drug-ADR combination is 
calculated, and if it is ˃9 it is categorized as definite, 5–8 as probable, 1–4 
as possible, and ˂ 1 as unlikely. WHO causality assessment scale and Karch 
and Lasagna’s causality assessment scale are also used to determine 
causality. Modified Hartwig and Siegel severity assessment scales are used 
to determine the severity of the suspected ADRs. Severity of a reaction was 
determined based on the classification systems of the WHO and system of 
Hartwig et al. The severity of a reaction was classified as Mild, Moderate, 
and Severe which, in turn, is categorized into different levels of which 
Level 1 and 2 is categorized as Mild, Level 3, 4a, and 4b is categorized as 
Moderate, and Level 5, 6, and 7 is categorized as Severe. Mild reactions 
will be resolved over a period of time with or without an antidote and 
without extending the period of hospital stay. Moderate reactions are 
those which require specific treatment and hospitalizations for at least 
1 day. Serious ADRs were considered as life-threatening leading to 
disability and required prolonged hospitalization usually in intensive care 
units. Preventability is measured using Modified Schumock and Thornton 
Preventability assessment scale. In this scale, it is categorized as definitely 
preventable, probably preventable, and not preventable based on a set 
of questions. Predictability of an ADR was done utilizing the Council of 
International Organization for Medical Sciences based on the incidence of 
the reactions reported in the available literature and the previous history 
of the reactions to the suspected drug under study [9].
Statistical analysis
Binary logistic regression was performed to identify the predictors 
contributing to the occurrence of ADR. Age, gender, the presence of 
comorbidities, route of administration, duration of stay, polypharmacy, 
diseases, and drugs were considered as the independent variable. 
p≤0.05 was considered as statistically significant. We compared the 
survival function of the subjects (occurrence of ADR) with respect to 
polypharmacy by plotting the Kaplan–Meier (KM) graph. Mantel–Cox 
statistics was performed for the comparison of KM components.
RESULTS
Percentage of occurrence of ADRs
In our study, a total of 250 patients were enrolled and of which, 
108 patients (43%) were presented with at least one ADR (Fig. 1).
Gender and age distribution based on ADR occurrence
The male and female patients with or without ADRs were assessed. Of 
78 females admitted 36 (46.2%) were found to have at least one ADR 
and of 172 males, 72 (41.9%) were found to have ADR (Fig. 2). Patients 
of all age groups were included in the study. Among patients between 
0 and 19 years, 5 (50%) patients showed a higher incidence of ADR 
followed by geriatrics in which 52 (48%) of 107 experienced ADR 
(Table 1).
Correlation of occurrence of ADRs with comorbidities
Comparing patients with and without comorbidities, patients with 
comorbidities were found to have more ADRs 77(71.3%) when 
compared to patients without comorbidities 31 (28.7%) (Table 2).
Correlation of occurrence of ADRs with number of drugs prescribed
More number of ADRs were seen in patients with polypharmacy (˃5 
drugs). 95(54%) patients experienced ADRs (Table 3).
Route of administration of suspected drugs
In our study, ADRs were commonly observed in orally administered 
drugs when compared to parenteral drugs (Fig. 3).
Correlation of occurrence of ADR with duration of stay
Correlation of occurrence of ADR with duration of stay was assessed, 
and the study revealed that occurrence of ADR prolonged the length of 
hospital stay (Table 4).
Correlation of occurrence of ADR with time
Delayed ADRs (>24 h) were found to be more when compared to rapid 
ADRs (within 24 h) (Fig. 4).
Occurrence of ADRs in neurological disorders
Patients diagnosed with epilepsy showed a higher percentage of 
incidences of ADRs when compared to other neurological disorders 
(Table 5).
Drug combinations involved in the pharmacokinetic and 
pharmacodynamic interaction
In the current study, 19 ADRs occurred due to pharmacokinetic and 
pharmacodynamic interactions, among which 11 reactions were due 
to pharmacodynamic interactions and 5 were due to pharmacokinetic 
interactions. The summary of the drug combinations involved in 
pharmacokinetic and pharmacodynamics is shown in Table 6.
Fig. 1: Percentage of occurrence of adverse drug reactions
Table 1: Age distribution in patients with or without ADR
ADR n (%)
0–19 years 20–39 years 40–59 years >60 years
Patients with ADR 5 (50) 19 (33.9) 32 (41.6) 52 (48.6)
Patients without ADR 5 (50) 37 (66.1) 45 (58.4) 55 (51.4)
Total number of patients 10 (100) 56 (100) 77 (100) 107 (100)
ADR: Adverse drug reactions
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Category of drugs based on ADR occurrence
Among the 212 ADRs observed, the highest rate of ADRs was observed 
in antiepileptics 61 (29.5%) followed by antihypertensives 27 (13%), 
anticoagulants 19 (9.2%), antibiotics 15 (7.2%), and antidiabetics 
11 (5.3%) (Table 7).
Among the commonly prescribed antiepileptics, levetiracetam 
19 (31.2%) was found to cause more number of ADRs followed by 
phenytoin 13 (21.3%), carbamazepine 8 (13.1%), gabapentin 6 (9.9%), 
and oxcarbazepine 5 (8.2%) (Table 8).
Analysis of ADRs based on the system
The organ system most commonly affected by ADRs were found 
to be gastrointestinal (GI) system 43 (20.3%) followed by CNS 
42 (19.8%) and dermatological system 23 (10.8%). The findings of 
the study showed that the most commonly reported ADR was found 
to be skin reactions 23 (10.8%) followed by constipation 18 (8.5%), 
giddiness 16 (7.5%), hyponatremia 13 (6.1%), tachycardia 11 (5.2%), 
hypokalemia 10 (4.7%), and headache 10 (4.7%) (Table 9).
Treatment of ADR
All the reactions were managed appropriately in our study. In 94 
reactions, either the suspected drug was withdrawn, and changes in 
doses were made, and in 111 reactions, specific antidote or treatment 
was given for the ADR. Continuous monitoring was done in 52 reactions 
to prevent the worsening of ADR (Fig. 5).
Assessment of ADR
The causality of ADR was assessed using three different scales, namely 
Naranjo’s Causality assessment scale, WHO causality assessment scale, 
and Karch and Lasagna’s causality assessment scale. Naranjo’s Causality 
assessment scale indicated that 149 (70.3%) ADRs were “probable” and 
63 (29.7%) ADRs were “possible.” WHO causality assessment scale inferred 
that 142 (67%) ADRs were “probable,” 64 (30.2%) ADRs were “possible,” 
and 6 (2.8%) ADRs were “unlikely.” Karch and Lasagna’s Causality scale 
showed that 145 (68%) of the ADRs were probable followed by possible 
(Fig. 6). The severity of the reported reactions was assessed using 
Modified Hartwig and Siegel Severity Assessment Scale which showed 
that 125 (59%) of the ADRs were categorized as moderate, 87 (41%) as 
mild, and none of the ADRs were found to be severe. In moderate reactions, 
Level 3 contributed to the highest percentage 93 (43.9%) (Fig. 7). The 
study revealed that 192 (90.6%) of the ADRs were “probable preventable” 
followed by “not preventable” 16 (7.5%) and “definitely preventable” 






With comorbidities 77 (71.3) 82 (57.7)
Without comorbidities 31 (28.7) 60 (42.3)
Total 108 (100) 142 (100)
ADR: Adverse drug reactions
Table 3: Correlation of occurrence of ADRs with number of 
drugs prescribed
Number of drugs per 
prescription
n (%)
2–3 drugs 4–5 drugs ˃5 drugs
Patients with ADR 3 (15) 10 (18.5) 95 (54)
Patients without ADR 17 (85) 44 (81.5) 81 (46)
Total 20 (100) 54 (100) 176 (100)
ADR: Adverse drug reactions
Table 4: Correlation of occurrence of ADRs with duration of stay
Duration of stay (days) n (%)
≤10 days ˃10 days
Patients with ADR 60 (33.1) 48 (69.6)
Patients without ADR 121 (66.9) 21 (30.4)
Total 181 (100) 69 (100)
ADR: Adverse drug reactions







Stroke 64 (43) 85 (57) 149 (100)
Epilepsy 18 (51.4) 17 (48.6) 35 (100)
Parkinson’s disease 4 (44.4) 5 (55.6) 9 (100)
Meningitis 8 (80) 2 (20) 10 (100)
Headache 1 (10) 9 (90) 10 (100)
Others 14 (37.8) 23 (62.2) 37 (100)
ADR: Adverse drug reactions
Fig. 2: Gender distribution based on adverse drug reactions 
occurrence
Fig. 3: Route of administration of suspected drugs
Fig. 4: Classification based on adverse drug reactions occurrence
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4 (1.9%) using Schumock and Thornton Preventability Assessment Scale 
(Fig. 8). The study suggests that majority of the ADRs were “predictable” 
156 (73.6%) when assessed by predictability scale (Fig. 9).
Outcomes
The outcomes of the suspected reactions were studied, and the results 
showed that 150 (70.1%), of our study subjects recovered from the 
reactions whereas 51 (24.1%) are still under recovery and 11 (5.2%) 
of reactions were continuing. 5.2% of the reactions were estimated to 
be continuing of which 6 (54.5%) reactions were mild and 5 (45.5%) 
reactions were moderate (Fig. 10).
Predictors of ADR
Binary logistic regression was analyzed (Table 10) and the predictors 
contributing to the occurrence of ADR was evaluated. Age, gender, 
presence of comorbidities, route of administration, duration of stay, 
polypharmacy, diseases, and drugs are the contributing factors. In this 
Table 6: Drug combinations involved in pharmacokinetic and pharmacodynamics interaction
Drug combination Interaction effect Mechanism of interaction Frequency
Enoxaparin+Clopidogrel+Aspirin Hemorrhage PD (Synergism) 2
Enoxaparin+Aspirin Hemorrhage PD (Synergism) 1
Glycopyrrolate+Ipratropium bromide Anticholinergic effects PD (Synergism) 2
Amantadine+Trihexyphenidyl Anticholinergic effects PD (Synergism) 2
Metoprolol+Telmisartan Hyperkalemia PD (Synergism) 1
Haloperidol+Ondansetron ECG changes PD (Synergism) 1
Nebivolol+Olmesartan+Hydrochlorothiazide Hypotension PD (Synergism) 1
Insulin+Metformin Hypoglycemia PD (Synergism) 1
Insulin+Telmisartan Hypoglycemia Unknown mechanism 1
Carbamazepine+Levetiracetam Ataxia Unknown mechanism 1
Carbamazepine+Levetiracetam Dizziness Unknown mechanism 1
Phenytoin+Clobazam Ataxia PK (metabolism) 2
Phenytoin+Clobazam Nystagmus PK (metabolism) 1
Phenytoin+Metronidazole Dizziness PK (metabolism) 1
Phenytoin+Clopidogrel Nystagmus PK (metabolism) 1
Table 7: Category of drugs based on ADR occurrence
Category: Suspected drugs n (%)
Antiepileptics (N03A): Phenytoin, Levetiracetam, Carbamazepine, Pregabalin, Oxcarbazepine, Clonazepam, Topiramate, Gabapentin, 
and Sodium valproate
61 (29.5)
Antibiotics (R02AB): Piperacillin+Tazobactam, Ceftriaxone, Linezolid, Ceftazidime, Meropenem, Tigecycline, and Cefuroxime 15 (7.2)
Antihypertensives (C02): Clonidine, Amlodipine, Metoprolol, Ramipril, Minoxidil, Mannitol, Telmisartan, Nebivolol, Losartan, 
Hydrochlorothiazide, Olmesartan, Furosemide, and Atenolol
27 (13)
Anticholinergics (R03BB): Tolterodine, Trihexyphenidyl, and Glycopyrrolate 10 (1.9)
Antidiabetics (A10): Insulin, Metformin, Glimepiride, and Sitagliptin 11 (5.3)
Skeletal muscle relaxants (M03): Baclofen 1 (0.5)
Analgesics (N02): Tramadol 5 (2.4)
Lipid-modifying agents (C10): Atorvastatin 2 (1)
Adrenergics, Inhalants (R03A): Salbutamol and Ipratropium bromide 5 (2.4)
Hemorrhagic cystitis inhibitor (R05CB): Mesna 5 (2.4)
Proton Pump Inhibitors (A02BC): Pantoprazole and Esomeprazole 3 (1.4)
Antiemetics (A04A): Ondansetron 6 (2.9)
Antineoplastics (L01): Rituximab 2 (1)
Vasopressin antagonists (C03XA): Tolvaptan 3 (1.4)
Corticosteroids for systemic use (H02): Betamethasone, Methyl prednisolone, and Dexamethasone 10 (4.8)
Cardiac glycoside (C01A): Digoxin 1 (0.5)
Antiarrhythmics (C01B): Amiodarone 1 (0.5)
Antigout preparations (M04A): Febuxostat 2 (1)
Anesthetics, general (N01A): Propofol 1 (0.5)
Thyroid Hormones (H03AA): Levothyroxine 1 (0.5)
Antiarrhythmics (C01B): Amiodarone 1 (0.5)
Antigout preparations (M04A): Febuxostat 2 (1)
Iron preparations (B03A): Elemental Iron 1 (0.5)
Antithrombotics agents (B01A): Dalteparin, Enoxaparin, Alteplase, Aspirin, Nicoumalone, Clopidogrel, and Cilostazol 19 (9.2)
Antipsychotics (N05A): Lithium, Quetiapine, and Haloperidol 5 (2.4)
Antifungals for systemic use (D01B): Voriconazole 1 (0.5)
Vitamins (A11): Vitamin B 1 (0.5)
Anesthetics, general (N01A): Propofol 1 (0.5)
Thyroid Hormones (H03AA): Levothyroxine 1 (0.5)
Antidepressants (N06A): Duloxetine and Venlafaxine 5 (2.4)
Antiparkinson drugs (N04): Carbidopa, Levodopa, and Entacapone 1 (0.5)
Antihistamines for systemic use (R06): Hydroxyzine and Chlorpheniramine 2 (1)
Total 207 (100)
Fig. 5: Treatment of adverse drug reactions
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study, association was observed in patients with polypharmacy (odds 
ratio - 0.236, 95% confidence interval [CI] 0.132-0.421, p=0.001), 
duration of stay (odds ratio - 4.203, 95% CI 2.323–7.602, p=0.001), 
in diseases such as stroke (odds ratio - 1.811, 95% CI 1.076–3.049, 
p=0.027) and epilepsy (odds ratio - 3.976, 95% CI 1.817–8.700, 
p=0.001) in patients using levetiracetam (odds ratio - 1.952, 95% CI 
1.096-3.477, p=0.027) and with comorbidities (odds ratio - 1.817, 95% 
CI 1.066-3.099, p=0.034). Association was not observed in age, gender, 
and route of administration.
KM analysis
We compared the survival function of the subjects with respect to 
polypharmacy by plotting the KM graph. The KM graph displays the 
cumulative survival function on a linear scale by polypharmacy. The 
survival curve of no polypharmacy (labeled as “0”) was lower than 
that of with polypharmacy (labeled as “1”), which means that no 
polypharmacy has a higher probability of surviving (not experiencing 
an event, ADR) than polypharmacy (logrank statistics, p=0.23) 
(Table 11 and Fig. 11).
DISCUSSION
The current study is a hospital-based prospective and observational 
study conducted among the inpatients of department of neurology. Of 
the 250 patients reviewed, 108 (43%) patients experienced at least one 
ADR. Among which 106 (98.1%) patients experienced ADR during their 
hospital stay and 2 (1.9%) patients were admitted due to the occurrence 
of ADRs. Our study showed an increase in the incidence of ADRs during 
the period of hospitalization which is in concordance with Nirojini et al., 
which stated that of total 295 patients, 157 patients experienced ADR 
during hospitalization [5].
In our study, a total of 172 male patients and 78 female patients 
were followed up of which 72 (41.9%) male patients and 36 (46.2%) 
female patients were presented with ADRs. Women were found to 
be affected with more number of ADRs when compared to men. This 
may be due to pharmacokinetic, pharmacodynamic, and hormonal 
changes in women. This finding is in agreement with Vijayakumar and 
Dhanaraju on the description of ADRs in a multi-specialty teaching 
hospital (2013) which expressed that more reports were observed 
Fig. 6: Causality assessment scales
Fig. 7: Modified Hartwig and Siegel severity scale
Fig. 8: Schumock and Thornton preventability scale
Fig. 9: Predictability scale













ADR: Adverse drug reactions
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in females (53.6%) compared to males (46.4%) [6]. Adolescents and 
geriatrics were most commonly affected with ADRs as observed in 
our study. This observation is contrary with the study of Palanisamy 
et al., on assessment, monitoring and reporting of ADRs in Indian 
hospital (2011) [10], where patients in the age group of 41–60 years 
(53.33%) contributed to the highest percentage of ADRs. Patients 
with comorbidities were found to have more ADRs when compared to 
patients without comorbidities 77 (71.3%). Maximum number of ADRs 
were seen in patients with polypharmacy which is in accordance with 
Ahmed et al. (2014) [11]. In our study, ADRs are commonly seen with 
orally administered drugs and delayed reactions were found to be more 
Table 9: Organ system classification of ADRs
System involved: Reactions n (%)
Gastrointestinal system disorders (0600): Loose stools (8), Constipation (18), Nausea and Vomiting (8), Gastric ulcer (1), Weight 
loss (1), Abdominal pain (2), and Dry mouth (5)
43 (20.3) 
Central and peripheral nervous system disorders (0410): Giddiness, Somnolence, Dizziness (16), Ataxia (8), Seizure (3), 
Headache (10), Fever (2) Neuroleptic Malignant Syndrome (NMS) (1), Slurred speech (1), and Insomnia (1)
42 (19.8)
Metabolic and nutritional disorders (0800): Hyponatremia (13), Hypokalemia (10), Hyperkalemia (2), Edema (9), Hypocalcemia (1), 
and Lactic acidosis (1)
36 (17)
Skin and appendages disorders (0100): Drug Reaction Eosinophilia and Systemic Symptoms (DRESS) (1), Rash (14), Xerosis (4), 
Erythema (4)
23 (10.8)
Heart rate and rhythm disorders (1030): Atrial fibrillation (1), Tachycardia with palpitations (11), ECG changes (2), and 
Bradycardia (1)
15 (7.1)
Red blood cell disorders (1210): Hemorrhage (7) and Anemia (7) 14 (6.6)
Vision disorders (0431): Conjunctivitis (2), Nystagmus (7), and Ptosis (3) 12 (5.7)
Respiratory system disorders (1100): Cough (6) 6 (2.8)
Platelet, bleeding and clotting disorders (1230): Thrombocytopenia (3) and Thrombocytosis (1) 4 (1.9)
Cardiovascular system disorders, general (1010): Hypotension (2) and Hypertension (2) 4 (1.9)
Endocrine disorders (0900): Hyperglycemia (1), Hypoglycemia (2), and Cushings syndrome (1) 4 (1.9)
Liver and biliary system disorders (0700): Hepatic injury (3) 3 (1.4)
Urinary system disorders (1300): Renal damage (2) and Urinary Tract Infection (UTI) (1) 3 (1.4)
Reproductive disorders, male (1410): Erectile dysfunction (2) 2 (0.9)
Musculoskeletal system disorders (0200): Rhabdomyolysis (1) 1 (0.5)
Total (100) 212 (100)
ADR: Adverse drug reactions
Table 10: Binary logistic regression result of predictors associated with ADR
Factor Odds ratio 95% CI* p value Adjusted odds ratio p value
Lower limit Upper limit
Age (Years)
≤55 1.613 0.974 2.670 0.074 -
˃55 Reference
Gender
Male 1.190 0.695 2.040 0.582 -
Female Reference
Comorbidities
Yes 1.817 1.066 3.099 0.034** -
No Reference
Route of administration
Oral 0.592 0.322 1.088 0.113 -
Parenteral Reference
Polypharmacy (Drugs)
˃5 0.236 0.132 0.421 0.001** 0.161 0.001**
≤5 Reference
Duration of stay (Days)
≤10 4.203 2.323 7.602 0.001** 0.288 0.001**
˃10 Reference
Stroke
Yes 1.811 1.076 3.049 0.027** 18.409 0.001**
No Reference
Epilepsy
No 3.976 1.817 8.700 0.001** -
Yes Reference
Levetiracetam
No 1.952 1.096 3.477 0.027** 2.809 0.013**
Yes Reference
Amlodipine
No 1.560 0.915 2.661 0.104 -
Yes Reference
*CI: Confidence interval, **Significance at 0.05
Table 11: Test of equality of survival distributions for the 
different levels of polypharmacy
Chi‑square df Sig.
Logrank (Mantel-Cox) 5.197 1 0.023
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which is in concordance with Lucca et al. The study finalized that the 
occurrence of ADR prolongs the length of hospital stay. 19 interaction-
led ADRs were observed among which 11 were pharmacodynamic 
and 5 were pharmacokinetic which is in par with Lucca et al., which 
stated that 27 (18.9%) reactions were pharmacokinetic and 98 (68.9%) 
reactions were pharmacodynamic [12].
The organ system most commonly affected by ADRs were found to be 
GI system 43 (20.3%) followed by CNS 42 (19.8%) which is in contrary 
with the study conducted by Nirojini et al. which observed that CNS 
(37.18%) was most commonly affected followed by GI (14.07%) [5]. 
The most commonly reported ADR was found to be skin reactions 
23 (10.8%) followed by constipation 18 (8.5%) which is on par with 
the study conducted by Vijaykumar et al. [6].
Patients diagnosed with epilepsy showed a higher incidence of ADR 
when compared to other neurological disorders. The highest rate of 
ADRs was recorded to be induced by AEDs 61 (29.5%) followed by 
antihypertensives 27 (13%) which is in conformity with Thuermann 
et al., on detection of ADRs in a neurological department [13]. Among 
the antiepileptics, levetiracetam 19 (31.2%) was found to cause more 
number of ADRs in contrary with Ramakrishna, on collection, detection, 
assessment, monitoring, and prevention of ADRs of antiepileptic drugs 
(2014) which inferred that phenytoin (44.7%) caused more number 
of ADRs [7]. According to the literature, most of the antiepileptic 
drugs have a narrow therapeutic index, therefore, therapeutic drug 
monitoring has to be employed to ensure safe and effective treatment. 
Monotherapy and regular follow-up of patients on antiepileptics should 
be considered to prevent the adverse reactions and to improve the 
patient’s compliance with drug therapy.
Among the total ADRs observed, 94 ADRs were managed either by 
withdrawing the suspected drug or by increasing or reducing the 
dose. Specific treatment along with or without a suitable antidote 
was given for 111 ADRs, to prevent further deterioration of reactions. 
This is contradictory to the study conducted by Vijayakumar et al. [14] 
which was conducted in intensive care and cardiac care units, where 
withdrawal of the drug was commonly initiated to manage the ADRs. 
In our study, administering an antidote or a specific treatment was 
the commonly adopted method. Abrupt cessation of the neurotropic 
drugs is not recommended as they lead to withdrawal complications; 
thus, dose has to be tapered slowly before it is withdrawn completely. 
Specific drug therapy has to be administered immediately on the 
appearance of an adverse reaction and/or an alternative can be 
prescribed.
Causality assessment scale showed that most of the ADRs were 
probably followed by possible. This study is in congruence with the 
study conducted by Singh et al., which illustrated that 36.36% were 
probably followed by possible with 31.16% [15]. The severity of the 
reported reactions was analyzed, and accordingly, 15 (59%) ADRs were 
categorized as moderate, 87 (41%) ADRs as mild and none of the ADRs 
were found to be severe. These findings were similar to the results 
of the study on Palanisamy et al. which confirmed that the majority 
of ADRs were moderate (58.33%) followed by mild (35%) [10]. The 
preventability assessment scale by Schumock and Thornton revealed 
that 192 (90.6%) ADRs were “probable preventable” followed by 
16 (7.5%) “not preventable” and 4 (1.9%) “definitely preventable.” 
Majority of the ADRs were “predictable” 156 (73.6%) as assessed 
by predictability scale. This study is similar to the study which is 
conducted by Raut et al., which proved that 45% of ADRs were “probably 
preventable” and 69% were “predictable” [16].
The outcomes of the suspected reactions showed that 156 (70.1%) 
study subjects recovered from the reactions. Severity and outcomes 
were correlated, most of the mild reactions showed faster recovery 
when compared to moderate reactions which were still under recovery. 
11 (5.2%) reactions were estimated to be continuing of which 
6 (54.5%) reactions were mild and 5(45.5%) reactions were moderate. 
These findings are in accordance with Vijayakumar and Dhanaraju 
where 77% recovered from reactions [6]. The early detection and 
management of adverse reactions can reduce health and economic 
burden on patients, and it also improves patients adherence and 
enhances health surveillance [17-19].
CONCLUSION
The study concludes that the prevalence of ADRs in the department 
of neurology is high. The literatures also support to this aspect, due 
to comorbidities and multiple drug regimens. Thus, early detection 
and management of ADRs are essential to avoid further progression of 
the reaction and its associated complications. Special attention should 
be provided to the patients who are at a higher risk of developing 
adverse reactions. Educational programs by clinical pharmacists will 
considerably reduce the complications thereby enhancing patient’s 
adherence to the drug therapy in achieving better therapeutic 
outcomes. Future studies can be conducted for a longer period of time 
in both inpatients and outpatients to compare the pattern of ADRs. 
Prescribing pattern and other DRP could be studied to improve the 
safety profile.
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